BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, January 23, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» Altamira Therapeutics and Univercells explore use of nanoparticle platform to deliver mRNA vaccines
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Drug Design, Drug Delivery & Technologies
Altamira Therapeutics and Univercells explore use of nanoparticle platform to deliver mRNA vaccines
March 26, 2024
No Comments
Altamira Therapeutics Ltd. has entered into a collaboration agreement with Univercells SA to evaluate the use of the company’s proprietary Semaphore platform for the delivery of mRNA vaccines.
BioWorld Science
Drug design, drug delivery and technologies
RNA
Collaboration
